Glenmark Life Sciences Limited Stock

Equities

GLS

INE03Q201024

Pharmaceuticals

End-of-day quote NSE India S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
815 INR +8.59% Intraday chart for Glenmark Life Sciences Limited +1.53% +24.03%

Financials

Sales 2024 22.83B 274M 374M Sales 2025 * 25.79B 309M 423M Capitalization 99.85B 1.2B 1.64B
Net income 2024 4.71B 56.48M 77.22M Net income 2025 * 5.5B 66.01M 90.25M EV / Sales 2024 4.17 x
Net cash position 2024 * 3.5B 41.96M 57.36M Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.87 x
P/E ratio 2024
20.2 x
P/E ratio 2025 *
18.2 x
Employees 1,824
Yield 2024 *
2.59%
Yield 2025 *
2.95%
Free-Float 15.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+8.59%
1 week+1.53%
Current month+4.93%
1 month+5.76%
3 months-2.54%
6 months+30.23%
Current year+24.03%
More quotes
1 week
743.85
Extreme 743.85
866.00
1 month
743.85
Extreme 743.85
866.00
Current year
655.65
Extreme 655.65
906.00
1 year
503.00
Extreme 503
906.00
3 years
370.00
Extreme 370
906.00
5 years
370.00
Extreme 370
906.00
10 years
370.00
Extreme 370
906.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-08-12
Director of Finance/CFO - 22-05-31
Compliance Officer - 21-02-22
Members of the board TitleAgeSince
Director/Board Member 66 20-10-29
Chief Executive Officer 58 19-08-12
Human Resources Officer 49 18-10-10
More insiders
Date Price Change Volume
24-04-26 815 +8.59% 584,264
24-04-25 750.5 -9.20% 589,960
24-04-24 826.5 +0.03% 24,936
24-04-23 826.2 -1.58% 88,182
24-04-22 839.6 +4.60% 109,398

End-of-day quote NSE India S.E., April 25, 2024

More quotes
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
815 INR
Average target price
905.8 INR
Spread / Average Target
+11.14%
Consensus

Quarterly revenue - Rate of surprise